{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:01:37Z","timestamp":1779328897550,"version":"3.51.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2022-1-4082"],"award-info":[{"award-number":["2022-1-4082"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500304"],"award-info":[{"award-number":["2021YFC2500304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200136"],"award-info":[{"award-number":["82200136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags\u00a0behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia \/lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.\n<\/jats:p>","DOI":"10.1186\/s13045-023-01406-8","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T04:10:39Z","timestamp":1677989439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting"],"prefix":"10.1186","volume":"16","author":[{"given":"Qiusha","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"issue":"1","key":"1406_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","volume":"14","author":"J-Z Hou","year":"2021","unstructured":"Hou J-Z, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14(1):66.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1406_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","volume":"2","author":"T Kamiya","year":"2018","unstructured":"Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor\u2013deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517\u201328.","journal-title":"Blood Adv"},{"issue":"30","key":"1406_CR3","first-page":"3340","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human. Phase I Trial J Clin Oncol. 2021;39(30):3340\u201351.","journal-title":"Phase I Trial J Clin Oncol"},{"issue":"Supplement 1","key":"1406_CR4","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1182\/blood-2022-169114","volume":"140","author":"R Chiesa","year":"2022","unstructured":"Chiesa R, Georgiadis C, Ottaviano G, Syed F, Braybrook T, Etuk A, Zhan H, Gkazi SA, Preece R, Adams S, Thomas R, Awuah A, Gilmour K, Mhaldien L, Chu J, Pinner D, Kubat A, Veys P, Rao K, Lucchini G, O\u2019Connor D, Vora A, Qasim W. Tvt CAR7: phase 1 clinical trial of base-edited \"universal\u201d CAR7 T cells for paediatric relapsed\/refractory T-ALL. Blood. 2022;140(Supplement 1):4579\u201380.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1406_CR5","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1182\/blood-2022-165733","volume":"140","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhou Y, Yang J, Li J, Qiu L, Ge W, Pei B, Chen J, Han L, Ren J, Lu P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood. 2022;140(Supplement 1):4566\u20137.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1406_CR6","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1182\/blood-2022-165819","volume":"140","author":"Y Tan","year":"2022","unstructured":"Tan Y, Pan J, Deng B, Ling Z, Weiliang S, Tian Z, Cao M, Xu J, Duan J, Wang Z, Wang K, Li C. Efficacy and safety of donor-derived CD7 CAR T cells for r\/r T-cell acute lymphoblastic leukemia\/lymphoma: interim analysis from a phase 2 trial. Blood. 2022;140(Supplement 1):4602\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1406_CR7","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2022-165822","volume":"140","author":"XFA Wong","year":"2022","unstructured":"Wong XFA, Ng J, Zheng S, Ismail R, Qian H, Campana D, Tan YX. Development of an off-the-shelf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing. Blood. 2022;140(Supplement 1):2358\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1406_CR8","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1182\/blood-2022-162222","volume":"140","author":"H Qian","year":"2022","unstructured":"Qian H, Gay FPH, Pang JWL, Lee Y, Ang J, Tan HC, Lek ES, Campana D, Tan YX. Development of anti-CD3 chimeric antigen receptor (CAR)-T cells for allogeneic cell therapy of peripheral T-cell lymphoma (PTCL). Blood. 2022;140(Supplement 1):4510\u20131.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01406-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T04:11:39Z","timestamp":1677989499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01406-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01406-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]},"assertion":[{"value":"26 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}